Lilly's Online, Interactive Health Education Program Receives Two Web Awards

LillyLilly USA recently was recognized by the eHealthcare Leadership Awards and the Web Marketing Association for its Health Education Answers program, an interactive health and wellness tool.

Health Education Answers is a free, Web-based program designed to help managed care and public payer organizations further drive the quality of patient care through educational outreach. This tool, which also is available in DVD-ROM format, educates patients on several health areas, including proper diet and exercise, healthy habits to teach children, and simple steps to help individuals and families prevent or manage illness.

At the 13th Annual Healthcare Internet Conference, Health Education Answers received an eHealthcare Leadership Award of Distinction for Best Care/Disease Management Site for the online tool's ability to help consumers manage a chronic condition, encourage two-way communication between patient and health care practitioners, and provide opportunities to monitor clinical care. More than 1,100 entries were received from a wide range of health care organizations, online health companies, pharmaceutical/medical equipment firms, suppliers and business improvement initiatives.

In addition, Health Education Answers received the 2009 Health Care Standard of Excellence Award from the Web Marketing Association. This award recognizes the people and organizations responsible for developing some of the most effective Web sites on the Internet today.

"Lilly is honored to be recognized by both the eHealthcare Leadership Awards and the Web Marketing Association for Health Education Answers," said Alex M. Azar II, vice president, Lilly USA. "These external awards give credibility to the fact that Health Education Answers is an easy-to-use and effective health and wellness program. We're proud to provide managed care and public payer organizations with this educational option that gives their plan members the tools they need to improve and maintain their health."

About Health Education Answers
Available in Spanish and English and with portions in Mandarin, Health Education Answers is based on research-supported patient education material that adheres to national clinical guidelines. Patients accessing the program can progress through several health and disease management modules, including ADHD, Bipolar Disorder, Depression, Diabetes, Diabetes Complications, Heart Health, Manage Your Weight, Medication Safety, Men's Health, Schizophrenia, Smoking and Addictions, Wellness and Women's Health.

The program also includes an optional health risk assessment, which helps patients identify and understand their individual health needs and at-risk behaviors. Based on the results, Health Education Answers directs patients to the most applicable education modules that provide tips for improvement.

The tool can be customized to meet each organization's individual needs, including incorporating the organization's logo, approved color palette, specific content selections and a personalized welcome message.

Other Recognitions
Health Education Answers received the Health on the Net Foundation's Code of Conduct (HONcode) certification. The HONcode is a voluntary certification system that aims to raise the quality of health care information available on the Internet. Health information Web sites that receive HONcode certification have been evaluated by the organization for providing reliable and credible health information, as well as data confidentiality, proper attribution of sources and transparency of financial sponsorship.

In 2008, Health Education Answers received Health Information Product Certification from the National Committee for Quality Assurance (NCQA) in the area of Health Risk Appraisals and Interactive Consumer Health Tools. NCQA is a private, nonprofit organization dedicated to providing health care quality information in order to help consumers, employers and others make more informed health care choices. Lilly is the first and only pharmaceutical company in the nation to receive this NCQA program status.

About Eli Lilly and Company
Eli Lilly and Company, a leading innovation-driven corporation, is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers - through medicines and information - for some of the world's most urgent medical needs. For additional information on Health Education Answers or Lilly's other patient care and disease management programs, visit www.lillyforbetterhealth.com.

Most Popular Now

Sanofi and GSK sign agreements with the Government…

Sanofi and GSK have signed agreements with the Government of Canada for the supply of up to 72 million doses of an adjuvanted COVID-19 vaccine, beginning in 2021. Thom...

Johnson & Johnson initiates pivotal global Pha…

Johnson & Johnson (NYSE: JNJ) (the Company) announced the launch of its large-scale, pivotal, multi-country Phase 3 trial (ENSEMBLE) for its COVID-19 vaccine candidate, J...

Scientists trace severe COVID-19 to faulty genes a…

More than 10 percent of young and healthy people who develop severe COVID-19 have misguided antibodies that attack not the virus, but the immune system itself, new resear...

Johns Hopkins researchers publish COVID-19 'predic…

Using a combination of demographic and clinical data gathered from seven weeks of COVID-19 patient care early in the coronavirus pandemic, Johns Hopkins researchers today...

Researchers uncover early results about an existin…

While scientists race to develop and test a vaccine effective against SARS-CoV-2, the virus that causes COVID-19, recent studies have indicated that countries with widesp...

Web resources bring new insight into COVID-19

Researchers around the world are a step closer to a better understanding of the intricacies of COVID-19 thanks to two new web resources developed by investigators at Bayl...

BioNTech and Pfizer initiate rolling submission to…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the initiation of a rolling submission to the European Medicines Agency (EMA) for BNT162b2, the lea...

Boost for global response to COVID-19 as economies…

64 higher income economies have joined the COVAX Facility, a global initiative that brings together governments and manufacturers to ensure eventual COVID-19 vaccines rea...

COVID-19 vaccine AZD1222 clinical trial resumed in…

The Phase I/II clinical trial for the COVID-19 vaccine AZD1222 has resumed in Japan after discussion with the Japanese Pharmaceuticals and Medical Devices Agency (PMDA). ...

Vir Biotechnology and GSK announce global expansio…

Vir Biotechnology, Inc. (Nasdaq: VIR) and GlaxoSmithKline plc (LSE/NYSE: GSK) announced the global expansion to Phase 3 of the COMET-ICE (COVID-19 Monoclonal antibody Eff...

Johnson & Johnson announces European Commissio…

Johnson & Johnson (NYSE: JNJ) (the Company) announced the European Commission (EC), acting on behalf of the European Union (EU) Member States, has approved an Advance Pur...

Adequate levels of vitamin D reduces complications…

Hospitalized COVID-19 patients who were vitamin D sufficient, with a blood level of 25-hydroxyvitamin D of at least 30 ng/mL (a measure of vitamin D status), had a signif...